For Sudha Seshadri, MD, professor of neurology and the founding director of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, fighting for brain health is personal.

A large, multi-site study funded by the National Institutes of Health aims to test the effectiveness of three existing drugs, including controversial ivermectin, to treat the symptoms of COVID-19. Known as ACTIV-6, the study is now underway at UT Health San Antonio.

A recent study validates use of a brief questionnaire to screen patients for chemical intolerance, after a large national sampling, and the researchers conclude the condition likely affects one in five people.

Researchers at The University of Texas Health Science Center at San Antonio, who see patients at University Health, are recruiting 900 adult COVID-19 survivors for a federally funded study that seeks to understand why some people have prolonged symptoms or develop new or returning symptoms after the acute phase of SARS-CoV-2 infection. The partnership also includes the Laredo Health Department as a clinical partner in this major effort.